<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331720</url>
  </required_header>
  <id_info>
    <org_study_id>FER-MEN-2006-03</org_study_id>
    <nct_id>NCT01331720</nct_id>
  </id_info>
  <brief_title>Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation</brief_title>
  <acronym>DESCARTES</acronym>
  <official_title>Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation Protocols Which Are the Most Common in Clinical Practice Using High Purified Gonadotrophins (u-FSH-HP y u-hMG-HP) in IVF/ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring SAU</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effectiveness of 5 mixed protocols of ovarian&#xD;
      hyperstimulation with urinary gonadotrophins to achieve clinical pregnancy in females&#xD;
      undergoing assisted reproductive techniques (IVF/ICSI) (in-vitro&#xD;
      fertilisation/intracytoplasmic sperm injection).&#xD;
&#xD;
      Study hypothesis: mixed protocols with urinary FSH (follicle-stimulating hormone) and urinary&#xD;
      hMG (human menopausal gonadotropin)should be more effective than monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>0-30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>0-16 days</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">279</enrollment>
  <condition>STERILITY</condition>
  <arm_group>
    <arm_group_label>FSH:LH 1:1 - Treatment Group A</arm_group_label>
    <description>Patients with a condition&#xD;
LH (luteinizing hormone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH:LH 3:2 - Treatment Group B</arm_group_label>
    <description>Patients with a condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH:LH 3:1 - Treatment Group C</arm_group_label>
    <description>Patients with a condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH:LH 3:0 - Treatment Group D</arm_group_label>
    <description>Patients with a condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E</arm_group_label>
    <description>Patients with a condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMG-HP</intervention_name>
    <arm_group_label>FSH:LH 1:1 - Treatment Group A</arm_group_label>
    <arm_group_label>FSH:LH 3:0 - Treatment Group D</arm_group_label>
    <arm_group_label>FSH:LH 3:1 - Treatment Group C</arm_group_label>
    <arm_group_label>FSH:LH 3:2 - Treatment Group B</arm_group_label>
    <arm_group_label>Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Females affected by sterility able to undergo IVF/ICSI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30&#xD;
&#xD;
          -  Prolactin within the laboratory normal range&#xD;
&#xD;
          -  Couples affected by sterility able to treat by IVF/ICSI (in-vitro&#xD;
             fertilisation/intracytoplasmic sperm injection)&#xD;
&#xD;
          -  Patients undergoing Menopur® and/or Bravelle® treatment&#xD;
&#xD;
          -  Normal thyroid function&#xD;
&#xD;
          -  Women not receiving clomifen citrate or gonadotrophins within one month prior study&#xD;
             start&#xD;
&#xD;
          -  Couples willing to participate in the study that have signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure in 3 previous cycles of assisted reproduction IVF/ICSI (in-vitro&#xD;
             fertilisation/intracytoplasmic sperm injection)&#xD;
&#xD;
          -  Policystic ovarian syndrome&#xD;
&#xD;
          -  Seminal samples not apt for IVF-ICSI (according to the criteria of each center)&#xD;
&#xD;
          -  Evidence of significant bacterial infection in the seminogram of the couple in the&#xD;
             preceding 6 months&#xD;
&#xD;
          -  Antecedents of severe ovarian hyperstimulation syndrome (OHSS)&#xD;
&#xD;
          -  Important systemic disease&#xD;
&#xD;
          -  Pregnancy or contraindication to pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Gijón</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Navarra</city>
        <state>Pamplona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site Sta. Cruz</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development Support</name_title>
    <organization>Ferring Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

